Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
bought more below 3 today - i don't know why. maybe the tax loss will have some value for me by year end ;)
[Delayed] VYNE Director LePore Adopts 10b5-1 Purchasing Plan
Additional News & Analysis at EZ-Insider
Complimentary access to this story is provided exclusively to Bloomberg users on a delayed basis.
To get real-time news stories or for a free trial of EZ-Insider, click here or call (301) 913-5100.
VYNE Director LePore Adopts 10b5-1 Purchasing Plan
10/8/2020
According to an 8-K filed on Oct. 7, VYNE Therapeutics Inc. (VYNE) Director Patrick G. LePore adopted his first 10b5-1 plan on Oct. 5. Under the plan, LePore may purchased up to 200,000 shares of the clinical stage biopharmaceutical company over the next 12 months, at prevailing market prices. The filing did not indicate when purchases under the plan would begin, and no other plan information was included in the filing.
H.C. Wainwright raises VYNE Therapeutics target
Oct. 05, 2020 3:24 PM ETVYNE Therapeutics Inc. (VYNE)By: Shweta Agarwal, SA News Editor1 Comment
VYNE Therapeutics (NASDAQ:VYNE) is up 10% after H.C. Wainwright reiterated its Buy rating and boosted its price target on ZILXI's (minocycline) entry to U.S. pharmaceutical market.
The firm raised its price target to $3.50 from $3, implying an approximately 97% upside.
Analyst Oren Livnat says: Amzeeq growth is on track, and Zilxi is about to launch with "coverage out of the gate and dermatologists eager for better rosacea treatment."
https://vynetherapeutics.com/press-releases/vyne-therapeutics-announces-zilxi-minocycline-topical-foam-1-5-is-available-in-pharmacies-nationwide-today-october-1st/
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st
ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults
ZILXI Offers Efficacy with Low Systemic Absorption
BRIDGEWATER, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its novel ZILXI™ (minocycline) topical foam, 1.5% is available as of today, October 1, 2020 by prescription for the treatment of inflammatory lesions of rosacea in adults. Approved by the U.S. Food and Drug Administration (FDA) in May 2020, ZILXI is the first minocycline product of any form to be approved by the FDA for use in rosacea, a diverse skin condition that most commonly presents with symptoms such as deep facial redness, spider veins (telangiectasia) and acne-like inflammatory lesions (papules and pustules). This new once-daily therapy will be available in retail, community and specialty pharmacies nationwide.
“Patients and physicians have been seeking new treatment options for rosacea, a condition that can be difficult to treat, leaving many patients dissatisfied and, in some cases, switching treatments multiple times or discontinuing altogether,” said David Domzalski, Chief Executive Officer of VYNE. “By combining a unique topical delivery system for minocycline with strong efficacy and tolerability, ZILXI is positioned to address a very challenging skin condition in a way that could change treatment considerations for rosacea.”
The Company also announced that the annual list price of ZILXI will be $485 per 30-gram canister, in parity with the wholesale price of AMZEEQ® (minocycline) topical foam, 4%, the Company’s topical minocycline indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. The Company is working to align contracts with commercial insurers, expanding efforts previously undertaken for AMZEEQ, to offer the broadest possible access to ZILXI for patients and healthcare professionals.
VYNE has also developed a multi-channel tactical marketing plan to reach customers, including deployment of the existing sales force to targeted rosacea-treating providers.
Minocycline is one of several broad-spectrum antibiotics known as tetracyclines with anti-inflammatory properties; their use in some patients is limited due to systemic side effects when taken orally. In ZILXI, VYNE has once more leveraged its proprietary Molecule Stabilizing Technology (MST™) platform to effectively deliver minocycline in a foam-based vehicle that contains naturally moisturizing ingredients, such as coconut and soybean oil, and is free of surfactants and drying agents.
ZILXI and AMZEEQ Important Safety Information
Indications
ZILXITM (minocycline) topical foam, 1.5% is for the treatment of adults with pimples and bumps caused by a condition called rosacea. It is not known if ZILXI is safe and effective in children.
AMZEEQ® (minocycline) topical foam, 4% is for the treatment of pimples and red bumps (non-nodular inflammatory lesions) that happen with moderate to severe acne in patients 9 years age and older. It is not known if AMZEEQ is safe and effective in children under 9 years of age or older.
ZILXI and AMZEEQ are both topical forms of the antibiotic minocycline and are available by prescription only. ZILXI and AMZEEQ are for use on skin only (topical use). ZILXI and AMZEEQ are not for use in the mouth, eyes or vagina.
Avita Therapeutics Access Event Set By Oppenheimer for Oct. 1
By Bloomberg Automation
(Bloomberg) -- Oppenheimer is hosting a corporate access company marketing event for Avita Therapeutics Inc. on Oct. 1.
==============================================
Title: Virtual: AVITA Therapeutics, Inc.
Summary: Oppenheimer will host a virtual company marketing with Avita Therapeutics Inc on October 1, 2020.
Host Contacts:
Corporate Access, OpcoCorpAccess@Opco.com
==============================================
Bloomberg data shows:
Oppenheimer Analyst Kevin Degeeter rates Avita Therapeutics outperform. Degeeter's price target of $45 implies another 86 percent return and is 25 percent above the consensus average of $36.02. Analyst price targets range from $5.91 to $60.
Avita Therapeutics has 7 buy recommendations, 0 holds and 0 sells
Market cap - $520.6 million
Short interest - 195,896 shares, representing 0.9 percent of the total float and 1.3 days average trading volume as of the latest data
The Relative Strength Index (RSI) indicates the company is neither overbought nor oversold
Shares of the company fell 4.3 percent in the last session to$24.25 and are down 46.7 percent this year
RCEL US Equity
Graphic Dashboard»
Related ticker:
RCEL US (Avita Therapeutics Inc)
To contact Bloomberg News for this story:
+1-212-617-2000 or newsauto@bloomberg.netThis story was produced by Bloomberg Automation.
FROM BTIG - report was dated 9/22/20
Avita Therapeutics, Inc.(RCEL, Buy, $41 PT)Takeaways from Investor Meetings: Burn Market Continues to Improve and Multiple Pivotal Trials Provide Upside to Shares; Reiterate Buy and$41
WHAT YOU SHOULD KNOW: On Monday, we hosted investor meetings with the RCEL mgmt. team that focused on a variety of topics, including recovery trends in the inpatient burn market, clinical trial timelines, progress on reimbursement and approval of RECELL 2.0 for outpatient burns, and other key value creation events. RCEL continues to be a name that many investors are just getting to know, but we expect interest in the company to continue to increase as we move towards a number of significant value creation events in 2021 that could expand RECELL's addressable market well beyond its current $200M. In our view, expansion into future indications has been relatively de-risked by RECELL's existing PMA for use in inpatient burns, and while there maybe some time before approval, we continue to think RCEL is attractive at these levels, especially for long-term investors. We are reiterating our Buy and $41 PT.
¦Update on progress in vitiligo pivotal trial. In July, the FDA approved RCEL's IDE application for a pivotal trial evaluating the RECELL System in vitiligo. The first patient was treated in this trial last week, and mgmt. repeatedly pointed to strong demand from both physicians and patients. In terms of trial design, 84 patients will be evenly split into three treatment arms with each group receiving a different dilution of spray-on skin cells (cell suspensions prepared at 1:5, 1:10, and 1:20)and NB-UVB for a portion of their depigmented lesion. For comparison, RECELL is typically used at a 1:80 dilution for burns, pediatric scalds, and trauma, and vitiligo patients that have been treated in the US to date have received cell suspensions prepared at 1:20. Each patient will also serve as their own control, with a portion of the depigmented lesion receiving treatment exclusively with NB-UVB. Mgmt. noted that there will be an interim readout after 33 patients at some point next year, but the company is still working with the FDA to figure out the exact primary outcome (although the study's page on clinicaltrials.gov — found here — defines responders as those patients who achieve at least 80% repigmentation). Enrollment is expected to be completed around this time next year, setting up RECELL for clearance potentially in FY22.
¦Current trends in inpatient burns. Recently, mgmt. announced that sales of the RECELL System in July were $1.8M, which represents the highest monthly sales since its US launch in January 2019. For FY1Q21, mgmt. is guiding to sales exceeding the $3.9M recorded in FY4Q20, and while this seems conservative considering results in July, it is worth noting that July is always the strongest month of the year. RCEL has historically reported detail around the number of burn centers with Value Analysis Committee (VAC) approval and burn surgeons trained on RECELL, bu tmoving forward we expect mgmt. to shift towards giving data around the number of unique account orders and physicians using the RECELL System. To that end, there were 57 unique account orders (out of 134 burn centers in the US) and more than 90 physicians (out of 300 burn surgeons in the US) used the RECELL System in July. We expect increased penetration and more frequent usage of RECELL among surgeons who have already adopted the product to drive top-line growth of ~75%and ~55% in FY21 and FY22, respectively.
¦Valuation: Our RCEL rating is Buy. Our $41 PT is based 10.5x our estimated FY24sales discounted back 2 years. Risks are discussed below. September 22, 2020
Ryan Zimmerman(212) 527-3586rzimmerman@btig.com
Max Smock(212) 588-6586 msmock@btig.com
Company Data Closing Price$26.82Price
Investment Thesis
With clinical data showing efficacy, improved cost-effectiveness over competitors, and lower donor site requirements relative to S.O.C., Avita’s foray in the US inpatient burn market is encouraging. More exciting is the broad array of potential treatment applications RECELL may be able to target combined with the technological simplicity of the product (~30 mins at the bedside).Avita has targeted future indications including outpatient burns, pediatric scalds, trauma, and vitiligo, which represent a $2B+ TAM. We see RECELL’s potential as even larger when considering potential applications in wound, aesthetics, and cell therapy.
Additional Takeaways
Status of reimbursement efforts and approval timeline for RECELL 2.0 in outpatient burns. While RECELL can currently be commercialized in the outpatient burn market without any further regulatory approvals, management is seeking incremental reimbursement and FDA approval of its next generation RECELL 2.0 to assist with market access. In regard to the former, mgmt. previously planned to seek a NTAP designation for RECELL, but based on feedback from CMS, the company is now pursuing a Traditional Pass-Through Payment Application (TPT) to support additional Medicare payment. Mgmt. indicated that the TPT has been submitted to the FDA, and the expectation is for a decision to be made by the end of 2020 which will go into effect at the beginning of 2021. Given RECELL's Breakthrough Status, there is a high likelihood that RCEL receives pass-through status for a period of time. In terms of FDA approval for RECELL 2.0, RCEL is in the final stages of preparing to apply for approval, and submission to the FDA is expected early in FY21. This is in line with previous commentary from mgmt. that FDA approval of RECELL2.0 is expected in the middle of 2021.Expansion into pediatric scalds and trauma likely at least a couple years away. RCEL's pivotal trials in pediatric scalds and trauma were initiated prior to its ongoing pivotal trial in vitiligo, but mgmt. was less specific around the timeline for approval in these indications. The company plans to assess the efficacy of RECELL in a minimum of 65 soft-tissue trauma patients, and while enrollment is starting to pick up, it is still going slower than anticipated due to COVID. In pediatric scalds, mgmt. plans to assess the efficacy of RECELL in 160 patients. RCEL continues to make progress with a few patients now enrolled and two new sites just coming online, but similar to the trial in soft-tissue trauma patients, the trial is expected to take at least a couple years. However, there is an interim readout from the pivotal trial in pediatric scalds planned at 80 patients, so we think investors will likely get an initial look at data at some point in late 2021 or early 2022.
Model Changes
RCEL recently filed a 10-K for the previous fiscal year denominated in USD. Our previous model, which we used while RCEL was domiciled within Australia, was built on AUD. As a result of the recent filing and the updated US-based domicile, we have updated our entire model to reflect RCEL's USD financial history.
BTIG, LLC Ryan Zimmerman (212) 527-3586www.btig.com3
would love to see $45 but i don't think anybody owns 61 million shares - there are 31.5 million outstanding with 25.1 million float - i'm happy it's only 31.5mm - they seem to have done a good job not diluting shareholders over time.
according to Bloomberg 16 insiders own 2.85% / 110 institutions own 28.35%
Chaim Lebovits has 124,740 shares, an increase of 31,185 as of 7/26/20
other insiders buying as well:
Ralph Kern has 151,540 +35,885 as of 3/06/20
Jacob Frenkel added 56,667 shares as of 3/30/20
Anthony Waclawski added 35,000 as of 9/8/20
Stacy Lindborg added 25,000 shares as of 6/1/20
David Setboun added 5,000 and owns 55,000 as of 7/16/20
Uri Yablonka added 10,000 as of 6/23/20
Artoro Arays added 3,000 as of 12/24/19
my apologies if i misunderstood the "61M" in your msg - and i also have no idea about option plans for management/employees.
GLTA - sure feels like the trend is up
sorry - maybe this will flow thru properly with target prices
VYNE US Equity
Firm Analyst Recommendation TARGET date
Cantor Fitzgerald Louise Chen overweight $15 9/10/20
Northland Securities Tim Chiang outperform $6 9/9/20
Cowen Ken Cacciatore outperform $10 8/24/20
ISS-EVA Casey Lea hold - 8/14/20
Barclays Dr Balaji V Prasad overweight $3 8/13/20
HC Wainwright Oren G Livnat buy $3 8/7/20
Piper Sandler David Amsellem overweight $5 8/6/20
Lifesci Capital Patrick Dolezal outperform $7 8/6/20
JMP Securities Donald B Ellis market outperform $24 3/9/20
not the best cut and paste from my bloomberg terminal but love all these price targets - hope we hit them all!! all pretty fresh except the last one --- if anyone has access to the actual reports please share...
VYNE US Equity
Firm Analyst Recommendation Tgt Px date
Cantor Fitzgerald Louise Chen overweight 15 9/10/20
Northland Securities Tim Chiang outperform 6 9/9/20
Cowen Ken Cacciatore outperform 10 8/24/20
ISS-EVA Casey Lea hold - 8/14/20
Barclays Dr Balaji V Prasad overweight 3 8/13/20
HC Wainwright & Co Oren G Livnat buy 3 8/7/20
Piper Sandler & Co David Amsellem overweight 5 8/6/20
Lifesci Capital Patrick Dolezal outperform 7 8/6/20
JMP Securities Donald B Ellis market outperform 24 3/9/20
Avita CMS Application Seen as Significant Catalyst: Bell Potter
By Tim Smith
(Bloomberg) -- Avita has filed a pass through payment application with the U.S. Centers for Medicare & Medicaid Services which has the scope to be a “significant catalyst” for the company, analyst John Hester writes in note.
If application is successful it would lead to reimbursement being paid separately for treatment of outpatient burns in both hospitals and surgical centers; Decision expected in early 2021
Clinical trials are continuing with first patient for the vitiligo study expected to be confirmed in Sept.
See enrollments of trauma and pediatric burns studies to restart before Christmas
Maintain buy; PT trimmed to A$15 from A$16
NOTE: Aug. 26: Avita Says July Unaudited Sales for RECELL System $1.83M
RCEL US Equity
Graphic Dashboard»
Related ticker:
RCEL US (Avita Therapeutics Inc)
To contact the reporter on this story:
Tim Smith in Sydney at tsmith58@bloomberg.net
Blackcrane Capital Buys 4.3% of Avita Therapeutics Inc.
By Bloomberg Automation
(Bloomberg) -- Blackcrane Capital took a new position in Avita Therapeutics Inc. in the second quarter, buying 4.3 percent of the company's outstanding stock.
For the company's full holders list, click here.
The investment advisor bought 921,663 shares with a current market value of $21.5 million, according to its 13F filing with the Securities and Exchange Commission.
Blackcrane Capital LLC initiated one other position in the health care sector during the quarter, bringing its total to six companies. At the end of the quarter, they comprised 69 percent, or $61.3 million, of the investment advisor's total equity holdings of $88.4 million disclosed in the 13F.
Avita Therapeutics traded at $23.34, down 49 percent year to date.
Bloomberg analyzed more than 4,300 institutional investors that are required to disclose their U.S. equity investments to the Securities and Exchange Commission each quarter. An algorithm searched for investors that had reported purchasing at least 1 percent of a company's shares in its latest filing and showed no holdings in the stock in the previous filing.
Old Mission Capital Buys 1.3% of Avita Therapeutics Inc.
By Bloomberg Automation
(Bloomberg) -- Old Mission Capital took a new position in Avita Therapeutics Inc. in the second quarter, buying 1.3 percent of the company's outstanding stock.
For the company's full holders list, click here.
The brokerage bought 269,579 shares with a current market value of $6.48 million, according to its 13F filing with the Securities and Exchange Commission.
Old Mission Capital LLC initiated 49 other positions in the health care sector during the quarter, bringing its total to 54 companies. At the end of the quarter, they comprised 7.8 percent, or $109 million, of the brokerage's total equity holdings of $1.39 billion disclosed in the 13F.
Avita Therapeutics traded at $24.03, down 47 percent year to date.
Bloomberg analyzed more than 4,300 institutional investors that are required to disclose their U.S. equity investments to the Securities and Exchange Commission each quarter. An algorithm searched for investors that had reported purchasing at least 1 percent of a company's shares in its latest filing and showed no holdings in the stock in the previous filing.
To see investor's holdings, click here.
RCEL US Equity
Graphic Dashboard»
Related ticker:
RCEL US (Avita Therapeutics Inc)
To contact Bloomberg News for this story:
+1-212-617-2000 or newsauto@bloomberg.netThis story was produced by Bloomberg Automation.
BTIG QUARTLY PREVIEW JULY 15,2020
Avita Medical (RCEL, Buy, $41PT): Earnings Preview:
Avita pre-announced top-line results for FY4Q20 and provided a company updateing early June. For the quarter, US RECELL System sales came in at A$6.0M (US$3.88M), which represents Q/Q growth of 2.4% and was above our estimate of A$5.5M (-5.4% Q/Q). Management previously estimated that the number of burn patients could decline up to 20% during the ongoing COVID pandemic as a result of nationwide protective orders driving a reduction in accidents. In spite of April results being the lowest monthly revenue and procedural volumes seen this calendar year, US RECELL System sales actually increased Q/Q, while estimated procedural volumes only decreased by ~4% Q/Q. It is also worth noting that Avita was able to add eight new accounts during the quarter (versus our estimate of five). The fact that Avita now has 77 total ordering accounts (represents ~60% of the total 132 US burn centers) is encouraging, but we expect COVID-19 to limit new customer acquisition efforts in the near-term. In spite of this, we think the clinical and economic benefits provided to existing customers will drive continued adoption at existing sites. Looking ahead, we expect investors will primarily be focused on updates around Avita’s plans to expand beyond inpatient burns into outpatient burns and vitiligo (as well as pediatric scalds and trauma to a lesser extent). While Avita can begin commercialization of RECELL in the outpatient burn market without any further regulatory approvals, management is seeking incremental reimbursement and FDA approval of its next generation RECELL 2.0 to assist with market access. Management expects FDA approval of RECELL 2.0 in the middle of 2021, which means commercialization will not begin until the back-half of 2021, at the earliest. In terms of reimbursement, Avita previously planned to seek a NTAP designation for RECELL, but due to the existence of long-standing CPT codes which providers may utilize in both the inpatient and outpatient hospital setting, CMS has advised management that the company does not have the ability to apply for a NTAP for use in the outpatient setting. Management has therefore elected to pursue a Transitional Pass-through Payment Application (TPT) to support separate additional Medicare payment for the RECELL System. Similar to the NTAP, if approved CMS would create a new C code and would allow the RECELL System to be billed and paid separately in hospital outpatient facilities and ASCs. RECELL's Breakthrough Device allows Avita to work with CMS through the next CMS scheduled quarterly review cycle. The company hopes to have a C code in place for the RECELL System at the start of 2021, which would set up the company to begin commercializing the product in the outpatient setting following FDA approval of RECELL 2.0 in the middle of 2021.Managementrecently announced that the FDA has approved its IDE application for a pivotal study evaluating RECELL in vitiligo, although the company is continuing to work with the FDA to finalize two outstanding study design considerations. Given management's expectations for enrollment in the pivotal trial to commence in the second half of CY20, we continue to think that the product could be approved by the end of 2021/early 2022. We previously published a deep dive piece on Avita's opportunity in vitiligo (More Than Skin Deep), and earlier in June we hosted an investor call focused on the use of RECELL for vitiligo. Our takeaways can be found here, and a replay of our call is embedded on BTIG's research portal. Beyond outpatient burns and vitiligo, Avita's pivotal trials evaluating RECELL in pediatric scalds and trauma were both initiated at the beginning of March 2020, but enrollment at clinical sites remains paused due to COVID. The company plans to assess the efficacy of RECELL in a minimum of 65 soft-tissue trauma patients, as well as in up to 160 patients with pediatric scald injuries. To date, Avita has only enrolled one patient in the soft-tissue trauma study and three patients in the pediatric scald study; however, management anticipates enrollment in both of these trials resuming in the ensuing quarter. We note that RCEL just recently completed its re domiciliation in the US, which should result in more visibility and awareness among investors; however, this comes at the cost of reduced float. While shares are still at elevated levels on an EV/Sales basis, we continue to believe that opportunities outside of inpatient burns are not accurately reflected in the company’s valuation. As a result, we view the recent pullback as an attractive entry point for long-term investors.
LLCRyan Zimmerman (212) 527-3586www.btig.com58HEALTHCARE INDUSTRY REPORT
Model Changes: We are not making any changes to our model at this time.
Valuation: Our $41 PT for RCEL is based on a sum-of-the-parts analysis. We value the existing business at $28 based on 5.0x our 2024 sales estimate of $120.9M discounted back 2.5 years at 9.3%. We add another $13 to the PT based on a 5-year discounted sales analysis of future indications in outpatient burn, pediatric scald, trauma ,and vitiligo.
MNLO mentioned under "12 new buys"
Franklin Templeton - Biotech Buys More Novavax, Cuts Biogen
By Bloomberg Automation
(Bloomberg) -- Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund added Horizon Therapeutics Plc to its investments and exited its position in Cara Therapeutics Inc. in the second quarter, according to data analyzed by Bloomberg.
The fund's disclosed holdings rose 34% in value to $1.76 billion. Evan McCulloch, Steven A Kornfeld and Wendy Lam Phd manage the fund.
Highlights:
Boosted Novavax Inc.
Reduced Biogen Inc.
Vertex Pharmaceuticals Inc. was the biggest investment, representing 7.4% of disclosed assets
12 new buys, including:
Horizon Therapeutics: 483,000 shares valued at $26.8 million
Royalty Pharma Plc Class A: 159,000 valued at $7.72 million
Vaxcyte Inc.: 228,000 valued at $7.21 million
Menlo Therapeutics Inc.: 3.87 million valued at $6.7 million, representing 2.3% of shares outstanding
Pliant Therapeutics Inc.: 200,900 valued at $6.52 million
Eight exited holdings, including:
Cara Therapeutics: 335,800 shares valued at $4.44 million
Minerva Neurosciences Inc.: 708,300 valued at $4.26 million
SpringWorks Therapeutics Inc.: 123,200 valued at $3.33 million
Arvinas Inc.: 77,300 valued at $3.12 million
Beam Therapeutics Inc.: 172,400 valued at $3.1 million
11 increased holdings, including:
Novavax: 88,100 shares, up 11% to 877,900 valued at $73.2 million, representing 1.5% of shares outstanding
Regeneron Pharmaceuticals Inc.: 20,300, up 12% to 194,300 valued at $121.2 million
Immunomedics Inc.: 361,200, up 35% to 1.39 million valued at $49.4 million
Reata Pharmaceuticals Inc. Class A: 96,300, up 41% to 333,500 valued at $52 million, representing 1.2% of shares outstanding
Insmed Inc.: 260,600, up 28% to 1.18 million valued at $32.5 million, representing 1.2% of shares outstanding
18 decreased holdings, including:
Biogen: 23,400 shares, down 7.9% to 272,310 valued at $72.9 million
Neurocrine Biosciences Inc.: 160,700, down 43% to 216,805 valued at $26.5 million
Iovance Biotherapeutics Inc.: 47,500, down 2.5% to 1.88 million valued at $51.6 million, representing 1.3% of shares outstanding
Gilead Sciences Inc.: 109,000, down 9.3% to 1.06 million valued at $81.8 million
UniQure NV: 110,500, down 45% to 136,200 valued at $6.14 million
Top holdings:
Vertex: down 18,100, to 445,662 shares valued at $129.4 million
Regeneron Pharmaceuticals Inc.: up 20,300, to 194,300 valued at $121.2 million
Amgen Inc.: down 10,000, to 422,200 valued at $99.6 million
Illumina Inc.: down 3,600, to 233,000 valued at $86.3 million
Gilead Sciences Inc.: down 109,000, to 1.06 million valued at $81.8 million
Franklin Templeton - Biotech returned 34% in the past year, underperforming the 38% return of its benchmark, Nasdaq Biotechnology Index. The fund returned 1.1% on an annualized basis over the past five years.
Click here to analyze the fund's holdings.Related tickers:
BIIB US (Biogen Inc)
CARA US (Cara Therapeutics Inc)
HZNP US (Horizon Therapeutics Plc)
INSM US (Insmed Inc)
IOVA US (Iovance Biotherapeutics Inc)
MNLO US (Menlo Therapeutics Inc)
NVAX US (Novavax Inc)
RETA US (Reata Pharmaceuticals Inc)
TEMBDAI LX (Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund)
Jugs - hope you don't mind if i use your crystal ball msg and adapt to my business. long Avita for 7 years. pre RS cost just below two bucks - sold some at 2.50 / 6 / 8 / 10 - its been a good ride...but filled with huge swings....better buyer here below 25. still have a nice LT cap gain on what i have left - about 20k shares post split. - IMHO covid has slowed progress but the train is and will continue to moved forward. share price will do what it does short term. long term, sales will increase, new uses and countries will get approval, and more recognition will come. over the years i've searched for competition to RCEL- some companies have tried and have made great promises, but in the end i can't find REAL COMPETITION ---- on a side note, also adding MNLO, and got lucky with BCLI purchase near $5 a few months ago. IN GENERAL - i'm very concerned with the overall market (changed my kids 529 plans to 80% cash - same with my 401k - trying to raise cash in several accounts if i can without incurring large taxes) but holding these 3 strong.
GLTA,
BillR05
Oppenheimer & Co initiated coverage of Avita Medical Ltd. ADRs with a recommendation of outperform.
PT set to $9, implies a 44% increase from last price. Avita Medical ADRs average PT is $9.67.
Targets range from $8 to $12
Avita Medical ADRs had 3 buys, 0 holds, 0 sells previously: Bloomberg data
https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_02202020_BCLI_Bautz.pdf
I found BCLI a few weeks ago while looking for any companies working on Post Polio Syndrome (FYI - it's really hard to find anybody doing trials on PPS) --- i'm no doc but ALS / MS / PPS all seem to breakdown the neurons that connect nerves to muscles....maybe they can try PPS at some point?
anyway - long from somewhere in the 4.25 area will hold until phase 3 results expected in the 4th quarter. I guess we either triple or get cut in half from this $6.00 area.
found this Zacks report released today --- enjoy.
https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_02202020_BCLI_Bautz.pdf
I found BCLI a few weeks ago while looking for any companies working on Post Polio Syndrome (FYI - it's really hard to find anybody doing trials on PPS) --- i'm no doc but ALS / MS / PPS all seem to breakdown the neurons that connect nerves to muscles....maybe they can try PPS at some point?
anyway - long from somewhere in the 4.25 area will hold until phase 3 results expected in the 4th quarter. I guess we either triple or get cut in half from this $6.00 area.
found this Zacks report released today --- enjoy.
https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_02202020_BCLI_Bautz.pdf
I found BCLI a few weeks ago while looking for any companies working on Post Polio Syndrome (FYI - it's really hard to find anybody doing trials on PPS) --- i'm no doc but ALS / MS / PPS all seem to breakdown the neurons that connect nerves to muscles....maybe they can try PPS at some point?
anyway - long from somewhere in the 4.25 area will hold until phase 3 results expected in the 4th quarter. I guess we either triple or get cut in half from this $6.00 area.
found this Zacks report released today --- enjoy.
New to the board - long time holder of Avita (2013) - Noticed on Friday we picked up new analyst coverage Down Under from Morningstar.
One source says .95 cent (ASD) target (Bloomberg). This article says .91 cents (closed at .70 last night). I'm good either way and happy to see Avita on a Global Best Ideas List! --- Nicolette Quinn is the analyst:
Avita Medical: skin in the game
Avita Medical develops and distributes regenerative products for the treatment of a range of wounds, scars, and skin defects.
Avita’s lead product, ReCell, is used in the treatment of a variety of burns, plastic, reconstructive and cosmetic procedures. The company operates in the Asia Pacific, the Americas, Europe, the Middle East and Africa.
“What sets ReCell apart from existing and new therapies is the speed at which it is able to create its Spray-on-Skin to apply to the burn site, as well as attractive pricing,” says Quinn.
ReCell has approval in the US for the treatment of second- and third-degree burns in adults, and Quinn sees potential for Avita to boost its market penetration in the next five years. It is expected to launch paediatric trials in fiscal 2022.
“While the company is currently loss-making, we forecast Avita to be profitable from fiscal 2022 and revenues to grow to $640 million by 2029.
“We expect the high forecast uncertainty is the likely reason for the market currently undervaluing Avita, but the latest results suggest approximately 20 per cent market penetration one year into commercial launch which affirms our longer run expectations of the product potential.”
Avita was up about 5 per cent in a sluggish market on Monday. It has a fair value estimate of 91c.
There are 11 Australian names in the Morningstar Global Best Ideas list. See the full selection here Morningstar Global Best Ideas list for February.